TRT before and after is best understood as a timeline of measurable effects. A review of published studies found sexual interest appearing after 3 weeks and body-composition changes within 12 to 16 weeks. Other changes took 6 months or longer, while several continued over years.1 Your starting symptoms and repeat morning testosterone measurements give those intervals clinical meaning.2 Published timelines describe groups of men. Your own results require measurement, physician review, and follow-up.
The Published TRT Results Timeline
Published testosterone effects begin and plateau on different schedules. A photograph cannot show when sexual interest changed, whether depressive mood improved, or how a laboratory marker moved. Measurements taken at defined intervals provide a clearer comparison.
The table below uses the intervals reported by Saad and colleagues in their review of published studies.1
| Effect | First Detectable | Maximum Effect | Source |
|---|---|---|---|
| Sexual interest | After 3 weeks | Plateauing at 6 weeks, with no further increments expected beyond | Saad et al.1 |
| Erections and ejaculations | May require up to 6 months | Not stated | Saad et al.1 |
| Quality of life | Within 3 to 4 weeks | Maximum benefits take longer | Saad et al.1 |
| Depressive mood | After 3 to 6 weeks | After 18 to 30 weeks | Saad et al.1 |
| Erythropoiesis | At 3 months | Peaking at 9 to 12 months | Saad et al.1 |
| Prostate-specific antigen (PSA) and prostate volume | Onset not stated | Plateauing at 12 months | Saad et al.1 |
| Lipids | After 4 weeks | After 6 to 12 months | Saad et al.1 |
| Insulin sensitivity | Within few days | Not stated | Saad et al.1 |
| Glycemic control | After 3 to 12 months | Not stated | Saad et al.1 |
| Fat mass, lean body mass, and muscle strength | Within 12 to 16 weeks | Stabilize at 6 to 12 months, but can marginally continue over years | Saad et al.1 |
| Inflammation | Within 3 to 12 weeks | Not stated | Saad et al.1 |
| Bone | After 6 months | Continuing at least for 3 years | Saad et al.1 |
First detection and maximum effect are separate points. Sexual interest appeared after 3 weeks in the review, while the reported plateau came at 6 weeks. Bone changes were detectable after 6 months and continued for at least 3 years.1 Your follow-up schedule should reflect the outcome your physician is measuring.
A Meaningful Baseline Before Therapy
An interpretable after result starts with a documented baseline. The Endocrine Society guideline recommends diagnosing hypogonadism only when symptoms and signs occur with unequivocally and consistently low serum testosterone concentrations. It also recommends confirming the diagnosis with a repeat morning fasting total testosterone measurement.2
Without baseline measurements, an after result has no clinical reference point. A change in energy, sexual function, mood, or body composition needs to be compared with your starting symptoms and labs. You can review low testosterone symptoms and the role of a testosterone blood test before discussing treatment.
The baseline also helps your physician decide whether testosterone therapy fits the clinical picture. If you need an overview of the treatment itself, see testosterone replacement therapy.
TRT Before and After at 3 and 6 Months
Body-composition changes follow a slower schedule than several sexual or mood effects. The Saad review places changes in fat mass, lean body mass, and muscle strength within 12 to 16 weeks. Those changes stabilize at 6 to 12 months and can continue marginally over years.1
A TRT before and after 3 months comparison may fall near the beginning of the published 12-to-16-week window. Six months marks the start of the review's 6-to-12-month stabilization window.1 Neither point guarantees a visible change or a specific result.
One trial found that androgen deficiency accounted for decreases in lean mass, muscle size, and strength. Estrogen deficiency primarily accounted for increases in body fat, while both contributed to declining sexual function. The amount of testosterone required to maintain these outcomes varied widely among men.3
The evidence does not provide belly-fat percentages, expected weight loss, or strength targets. Your physician needs repeat measurements that can be compared with the same baseline measures.
Variation Between Individual Timelines
The same treatment schedule can produce different timelines among men. The Saad review says this variation is probably related to the pharmacodynamics of the testosterone preparation. It also names genomic and non-genomic effects, androgen receptor polymorphism, and intracellular steroid metabolism as contributing factors.1
The review does not provide a formula that predicts your response from those factors. The Finkelstein trial also found wide variation in the amount of testosterone required to maintain lean mass, fat mass, strength, and sexual function.3
Another person's result can provide context, but it cannot set your expected timeline. Your baseline and repeat measurements give your physician a more useful comparison.
Published Intervals and Individual Expectations
The review reports erythropoiesis becoming evident at 3 months and peaking at 9 to 12 months.1 Management of related laboratory changes belongs with your prescriber. A separate guide explains hematocrit on TRT in more detail.
Treatment Decisions and Ongoing Monitoring
A TRT results timeline does not decide whether therapy is appropriate. The Endocrine Society recommends testosterone therapy for symptomatic deficiency after discussing potential benefits, risks, and monitoring with the person receiving treatment.2
The guideline recommends against starting therapy when you are planning fertility in the near term. It also lists breast or prostate cancer and a palpable prostate nodule or induration among the conditions that weigh against starting treatment.2
Monitoring remains part of the treatment decision after therapy begins. Your physician can compare follow-up symptoms and measurements with your original baseline, then decide whether the plan needs adjustment. For a separate discussion of treatment effects, see the benefits of TRT.
The route and the site are set by the product. Testosterone injection routes and sites works through what each label specifies. Testosterone aromatizes to estradiol, so raising one raises the substrate for the other. The male estradiol reference interval explains what that number is read against.
The Opt Take on TRT Before and After
A physician should interpret your labs against your symptoms and goals, build your plan, and adjust it as new measurements come in. A dashboard or transformation photo cannot do that work.
At Opt Health, we start with a panel of 55+ biomarkers. A physician reviews the results with you, and labs plus a physician consultation repeat every 3 to 4 months. The plan is adjusted based on what your numbers did. You can read more about how the Opt process works.
TRT before and after becomes a documented baseline, a follow-up measurement, and a physician-led decision about the next interval.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
The timing depends on the effect being measured. The Saad review found sexual interest appearing after 3 weeks and plateauing at 6 weeks. Body-composition changes occurred within 12 to 16 weeks and stabilized at 6 to 12 months. Bone effects were detectable after 6 months and continued for at least 3 years.1 These intervals describe published studies and do not guarantee your individual timeline.
The cited evidence supports changes in overall fat mass, but it does not isolate belly fat or promise fat loss in a specific area. The Saad review places fat-mass changes within 12 to 16 weeks, with stabilization at 6 to 12 months.1 One trial also found wide variation in the amount of testosterone required to maintain fat mass among men.3
TRT requires a physician-led discussion of potential benefits, risks, and monitoring. The Endocrine Society recommends therapy for men with symptomatic testosterone deficiency after that discussion.2 It recommends against starting when you are planning fertility in the near term or have breast or prostate cancer, or a palpable prostate nodule or induration.2 Your diagnosis, fertility plans, and medical history belong in the consultation before treatment begins.
No cited source supports calling human growth hormone (HGH) better than TRT. The sources used for this timeline contain no direct comparison between the two treatments. A comparison would require evidence that measures both treatments for the same diagnosis and outcomes. Read about human growth hormone separately, then discuss the relevant diagnosis with a physician.
The available sources do not provide a testicular size or percentage change. A systematic review of anabolic androgenic steroid use at non-replacement doses reported reductions in luteinizing hormone during intake.4 That evidence concerns anabolic-steroid use among athletes and recreational users, so it cannot quantify testicular changes during prescribed TRT. Fertility and testicular effects should be discussed with your physician before treatment.
We do not speculate about Joe Rogan's medical treatment. Celebrity anecdotes cannot establish a diagnosis, treatment plan, or expected TRT timeline for you. Your decision should be based on symptoms, repeated morning testosterone measurements, and physician review.2
References
- Saad F, Aversa A, Isidori AM, Zafalon L, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675-85. https://pubmed.ncbi.nlm.nih.gov/21753068/
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-22. https://pubmed.ncbi.nlm.nih.gov/24024838/
- Christou MA, Christou PA, Markozannes G, Tsatsoulis A, et al. Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis. Sports Med. 2017;47(9):1869-1883. https://pubmed.ncbi.nlm.nih.gov/28258581/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.